Navigation Links
Colonoscopy screening every ten years could prevent 40% of colorectal cancers
Date:9/22/2013

deaths from the disease.

They found that both colonoscopy and sigmoidoscopy -- which screens for tumors in the distal, or lower part of the colorectum -- were associated with decreased risk of either getting colorectal cancer or dying from it. Only colonoscopy decreased the risk for cancers originating in the proximal colon, but not to the degree of its protective effect against distal colorectal cancers. The researchers suggested that colonoscopy's smaller effect in reducing risk for tumors in the proximal colon might be due in part to molecular or biological differences in those cancers.

Other findings include:

  • The researchers estimated that if all participants in the study had undergone colonoscopies, 40% of colorectal cancers -- including 61% of distal cancers and 22% of proximal cancers -- would have been prevented.

  • Sigmoidoscopy alone is likely insufficient for reducing the incidence or death risk of colorectal cancer that originates in the upper colon.

  • People who get a clean bill of health after a colonoscopy have a significantly reduced risk of colorectal cancer for up to 15 years after the procedure, although the data support repeat screening at shorter intervals among individuals with a personal history of adenoma -- a benign tumor of glandular origin that can become malignant over time -- or a family history of colorectal cancer.

  • Colorectal cancers diagnosed within five years of a colonoscopy had different molecular characteristics compared with cancers diagnosed more than five years after a colonoscopy, and they may be difficult to detect or completely remove.

"Each year, more than 1.2 million people are diagnosed with colorectal cancer worldwide. Our findings could help improve and strengthen the current guidelines for colorectal cancer screening," said Reiko Nishihara, lead author and research fellow in the Department of Nutrition at HSPH.

Support
'/>"/>

Contact: Marge Dwyer
mhdwyer@hsph.harvard.edu
617-432-8416
Harvard School of Public Health
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
2. SpermCheck® Fertility, the Only FDA Approved At-Home Screening Test for Men to Determine Normal or Low Sperm Count, Now Available to Couples Planning or Struggling to Conceive
3. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
4. Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
5. BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment
6. Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
7. Genedata Screener for HCS Advances Phenotypic Screening
8. IntelliCyt Introduces New System for Multiplexed Screening of Suspension Assays
9. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
10. Charm Sciences EZ System Accepted for Antibiotic Testing of Raw Milk in the US NCIMS Residue Screening Program
11. Seeing the Future: How a Revolutionary New Bacterial Screening Device can Predict a Patient’s Future for Tooth Decay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... at the 35 th Annual Canaccord|Genuity Growth Conference ... "Pete" Petit, Chairman and CEO, William C. Taylor ...
(Date:8/3/2015)... , August 3, 2015 ... the commercialization of its Bio-electrical Signal Therapy device ("BST ... treatment of hard to heal chronic wounds, today announced ... with Chemipal, an Israeli distributor specializing in medical devices, ... Chemipal is a 70 years old, sales, ...
(Date:7/31/2015)... In today,s fast changing healthcare environment, ... positive health outcomes, improve profitability and enhance their ... in their communities. At ThoughtSpot 2015, Good ... announced a new set of innovative capabilities that ... help independent pharmacies endure the industry,s most pressing ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader ... today that the Company,s second quarter ended June 30, 2010 ... Monday, August 9, 2010 .  The management team of Osteotech ... 9, 2010 , at 9:00 a.m. (EDT) to discuss ...
... Mass. , Aug. 4 New England ... Michael Smith Genome Sciences Center has selected New England ... sequencing library construction reagents. NEBNext DNA Sample Prep Reagent ... and validated for sample preparation for next generation sequencing, ...
... Elusys Therapeutics, Inc. (Elusys), a privately-held ... second contract year of funding valued at $40.6 million ... and treatment of anthrax infection following a biowarfare attack. This ... received under this contract and is part of a potential ...
Cached Biology Technology:Osteotech Announces Second Quarter 2010 Financial Results Release and Conference Call 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 3Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 2Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 3
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... Vermillion, Inc. (NASDAQ: VRML ), a ... health, announced the signing of a cooperative research and development ... Materiel Command (USAMRMC). The agreement kicks off ... Treatment Algorithm for Adnexal Masses in Women," and follows ...
... is pleased to announce it has received a grant ... Advanced Life Sciences Training Program. The grant will ... July 2013 for all five classes of participants in ... 2008. The Fellows Program is a high-level life science ...
... KISS 1 is a metastasis-suppressor gene which helps to ... ovarian cancers to name a few. But new ... Dentistry shows that kisspeptins peptide products of KISS1, actually ... grade and metastatic potential. The research is published ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4Keystone Symposia announces grant from Alfred P. Sloan Foundation 2
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: